Cargando…
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra(®)), is a humanized m...
Autores principales: | Patel, Aarat M, Moreland, Larry W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990387/ https://www.ncbi.nlm.nih.gov/pubmed/21116333 http://dx.doi.org/10.2147/DDDT.S14099 |
Ejemplares similares
-
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Mihara, Masahiko, et al.
Publicado: (2011) -
Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008) -
Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014) -
Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
por: Kumar, Abhishek, et al.
Publicado: (2022) -
Unmet needs in rheumatoid arthritis
por: Moreland, Larry
Publicado: (2005)